Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

开始日期2026-08-01

申办/合作机构-

NCT06790394

/ Not yet recruiting临床1期

A Test-retest Study to Evaluate the Reproducibility of [18F]Florbetaben PET Imaging in Patients With Cardiac Amyloidosis and Control Patients

This study is an open-label study to evaluate and characterize test-retest reliability of [18F]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the [18F]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of [18F]florbetaben uptake in the heart will be performed.

开始日期2025-06-01

申办/合作机构

Life Molecular Imaging Ltd.

[+1]

NCT07012993

/ Recruiting临床2期IIT

Evaluation of Ultralow Dose PET Imaging for Detecting Amyloid Tracer Uptake

The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamol and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours

开始日期2025-05-20

申办/合作机构

Nuclear Energy Institute

100 项与氟贝他吡[18F] 相关的临床结果

登录后查看更多信息

100 项与氟贝他吡[18F] 相关的转化医学

登录后查看更多信息

100 项与氟贝他吡[18F] 相关的专利（医药）

登录后查看更多信息

432

项与氟贝他吡[18F] 相关的文献（医药）

2025-05-04·Journal of Sulfur Chemistry

Small molecule heterocycles: design and synthesis of novel fluorescent Benzothiazoles for early detection of Alzheimer’s disease

作者: Sharma, Vijay ; Sundaram, G.S.M.

Diagnostic agents capable of imaging β-amyloid (Aβ) plaques at prodromal stages could provide noninvasive tools to assess plaque burden and assist in determining efficacy of disease-modifying therapeutic interventions in vivo.To accomplish this goal, FDA approved 18F-incorporated tracers, such as Florbetapir, Flutemetamol, and Florbetaben may allow quant. anal. of therapeutic efficacy of disease-modifying treatments that attenuate Aβ pathophysiol. in vivo.Although promising, these tracers show high off-target binding.Importantly, current anti-amyloid therapy also targets diffuse amyloid plaques (included in revised NIAAA criteria for detecting AD) and other forms of amyloid plaques.Therefore, mols. capable of detecting both diffuse and fibrillar plaque pathol. can potentially offer better quant. tools for interrogating efficacy of anti-amyloid therapy.To achieve this goal, herein, we report synthesis and characterization of new small organic mols.: ((Z,E)-4-(2-(6-(2-Fluoroethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline), ((Z)-4-(2-(6-(2-(2-(3-Fluoropropoxy)ethoxy)ethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline) and ((E)-4-(2-(6-(2-(2-(3-Fluoropropoxy)ethoxy)ethoxy)benzo[d]thiazol-2-yl)vinyl)-N,N-dimethylaniline) We also report preliminary investigations on binding affinity in vitro.While demonstrated a relatively higher affinity, both and showed moderate affinity for Aβ1-42 aggregates in vitro.Furthermore, all 3 agents showed ability to detect Aβ fibrillar and diffuse plaque pathol. in brain sections of APP/PS1 transgenic mice and post-mortem confirmed AD human brain tissue sections.

2025-05-01·Brain and Behavior

MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [¹⁸F] AV45 and FDG PET Imaging

Article

作者: khezragha, Delnia ; Barati, Reza ; Taghizadeh Khorshidi, Shaghayegh ; Darvishi, Afra ; Farhadieh, Mohammad‐Erfan ; Safavi, Seyed Ahmad Reza ; Shakeri, Shayan ; Mayeli, Mahsa ; Hatami Nejad, Mohamad ; Gulisashvili, David ; saberian, Parsa ; Sadeghi, Mohammad ; Sedighi, Sara ; Forouzandegan, Moojan

Abstract:

Purpose:

Alzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.

Method:

Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([18F]AV45 and FDG PET, respectively).

Findings:

The study found a significant positive correlation between CSF levels of miR‐210‐3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR‐223‐3p levels were significantly lower in APOE‐ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let‐7g‐5p, mir‐423‐5p, and mir‐660‐5p were negatively associated with glucose reuptake in the brain.

Conclusion:

Elevated levels of miR‐210‐3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.

2025-02-01·Journal of Nutrition Health & Aging

Impact of diabetes on the progression of Alzheimer’s disease via trajectories of amyloid–tau–neurodegeneration (ATN) biomarkers

Article

作者: Kim, Eosu ; Kim, Eun Woo ; Kim, Keun You

BACKGROUND:

Alzheimer's disease (AD) is characterized by the accumulation of abnormal proteins, such as β-amyloid and tau, in the brain, which precedes cognitive impairment. Although diabetes mellitus (DM) is a well-established risk factor for AD, few studies have investigated how the presence of DM affects the sequential pathogenesis of AD, specifically within the amyloid-tau-neurodegeneration (ATN) and cognition framework.

OBJECTIVES:

This study aims to investigate the trajectories of ATN biomarkers in relation to the presence of DM in the preclinical and prodromal stages of AD.

DESIGN:

Participants with normal cognition (CN) or mild cognitive impairment (MCI) at baseline were included. Subjects were followed for 12-192 months, with neuroimaging and cognitive assessments conducted at every 12 or 24 months.

SETTING:

This study utilized data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.

PARTICIPANTS:

A total of 603 participants aged 55-90 years were included, comprising 284 CN (25 with DM, 259 without DM) and 319 MCI (39 with DM, 280 without DM) individuals.

MEASUREMENTS:

ATN biomarkers were identified using florbetapir positron emission tomography (PET), flortaucipir PET, and magnetic resonance imaging (MRI), respectively. Cognition was assessed using the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and Mini-Mental State Examination (MMSE). Moderation analysis was conducted to investigate the effect of DM on the association between ATN biomarkers of AD.

RESULTS:

Elevated amyloid standardized uptake value ratios (SUVRs) were associated with increased tau levels in the hippocampus, and this association was significantly enhanced by the presence of DM in MCI participants (p = 0.021). DM also strengthened the association between increased tau SUVR levels and neurodegeneration (indicated by decreased entorhinal cortical volumes; p = 0.005) in those with MCI. Furthermore, DM enhanced the association of decreased entorhinal (p = 0.012) and middle temporal cortex (p = 0.031) volumes with increased (worsened) CDR-SB scores in MCI participants. However, DM did not predict significant longitudinal changes in ATN pathology or cognitive decline in CN participants.

CONCLUSIONS:

Our study suggests that DM may increase the risk of AD by accelerating each step of the A-T-N cascade in the prodromal stage of AD, underscoring the importance of DM management in preventing the MCI conversion to AD.

项与氟贝他吡[18F] 相关的新闻（医药）

2025-06-15

·PRNewswire

Statement from the Alzheimer's Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder

The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ -- It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co-Founder and Chairman, Leonard A. Lauder. A visionary philanthropist, cosmetics industry icon, and steadfast champion in the fight against Alzheimer's disease, Lauder's legacy is woven into the very fabric of the ADDF and the progress it has driven toward understanding, treating, and ultimately curing Alzheimer's. "Leonard Lauder was a once-in-a-generation visionary whose leadership, along with his brother Ronald, reshaped the Alzheimer's research landscape," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "From the very beginning, Leonard understood that Alzheimer's does not just impact the patient, it affects entire families. The Lauder family recognized the emotional, financial, and societal toll of this disease, and built the ADDF to accelerate the discovery and development of treatments that could change the trajectory for patients and their loved ones. Leonard's vision, generosity, and humanity spanned across his business acumen to his philanthropic endeavors, touching countless lives, and his legacy will endure in every breakthrough we help bring forward." Lauder and his brother, Ronald S. Lauder, co-founded the ADDF in 1998 with Dr. Fillit in honor of their mother, Estee Lauder's, battle with Alzheimer's. At a time when Alzheimer's research funding was sparse and interest from the private sector limited, the Lauder family recognized the urgent need for treatments and created a bold new venture philanthropy model to achieve this mission, combining the rigor of scientific research with the agility and entrepreneurialism of venture capital. For over more than 27 years, the Lauders' leadership helped shape the ADDF into the world's leading philanthropic funder of drug discovery and development research. Under the Lauders' guidance, the ADDF has: Invested more than $370 million into over 765 drug discovery programs across 21 countries Catalyzed more than $3 billion in follow-on funding from pharmaceutical companies, venture capital firms, and government agencies, helping to de-risk early-stage science and attract broader investment into Alzheimer's research Played a pivotal role in the development of the first biomarkers for Alzheimer's by providing early seed funding for Amyvid, the first FDA-approved PET scan for Alzheimer's; PrecivityAD, the first Alzheimer's blood test to market; and Lumipulse, the first Alzheimer's blood test to receive FDA approval Established the Diagnostics Accelerator (DxA) in partnership with Bill Gates and other visionary philanthropists to advance affordable, accessible diagnostic tools, a critical step toward earlier detection and intervention Advanced a diverse pipeline of treatments by pioneering the biology of aging approach, now central to the field, with over 70% of drugs targeting disease pathways such as inflammation, neuroprotection, vascular health, and synaptic function, paving the way for Alzheimer's to be treated with combination therapy and precision medicine, as in cancer Brought forward a precision prevention approach, combining lifestyle interventions and therapeutics to slow the progression or prevent the onset of Alzheimer's altogether Through all these achievements, Lauder and his family remained deeply committed to the ADDF's mission. "Leonard's impact on the ADDF, and on the field of Alzheimer's research more broadly, is immeasurable," said Mark Roithmayr, Chief Executive Officer of the ADDF. "He brought a sense of urgency to this work that pushed us all to do more and move faster. He believed that patients and families deserve better and he committed himself fully to building a world in which effective treatments are not only possible, but inevitable. His leadership, his generosity, and his humanity will continue to guide the ADDF's mission every day." Lauder's impact extended across business, culture, and philanthropy. Yet for those who worked alongside him at the ADDF, he will be remembered most for his compassion, clarity of purpose, and unwavering belief in progress. He understood that Alzheimer's is a deeply human and societal challenge, one affecting memory, identity, and dignity. The ADDF honors Lauder's legacy by reaffirming our commitment to conquer Alzheimer's for the millions of patients and families living with this devastating disease. About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-06-02

·PRNewswire

The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (DxA) Invests in Expansion of Quality Control Program for Blood and CSF Biomarkers

New investment helps to ensure patients can access high-quality and reproducible testing across labs worldwide NEW YORK, June 2, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced an investment of up to $2M to expand a quality control program for blood and CSF biomarkers, titled the University of Gothenburg Quality Control Program supported by the Diagnostics Accelerator (DxA) and Global Biomarker Standardization Consortium (GBSC). The program, led by global Alzheimer's experts Henrik Zetterberg and Kaj Blennow from the University of Gothenburg, will ensure consistent, high-quality, and reproducible testing is conducted across labs worldwide, allowing for head-to-head comparisons between tests as well as more standardized and reliable tests for patients. "The Alzheimer's field is evolving rapidly with advances in biomarkers bringing new and novel tests to market as part of our efforts to provide patients with an early and accurate diagnosis," said Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF. "While regulatory clearance and testing provides some control, the volume and diversity of testing being conducted creates a pressing need for the expansion of quality control efforts in more labs. A core tenet of the Diagnostics Accelerator (DxA) is to accelerate the development of accessible, reliable, and capable diagnostic tools. This program is an important step forward in ensuring that patients worldwide receive an accurate and consistent diagnosis regardless of the test setting." The Alzheimer's quality control program launched in 2009 with the goal of establishing a tool to monitor the performance of cerebrospinal fluid (CSF) biomarker measurements across clinical laboratories and large research laboratories, while also protecting against longitudinal drift and batch-to-batch variations. The program has grown to include blood biomarkers across multiple platforms. The DxA's investment will enable the expansion of the program beyond the current 120 labs, ensuring quality control will be available beyond the existing six testing platforms. As testing and treatment becomes more widespread, quality control and proficiency testing programs will become a regulatory necessity to guarantee high-quality testing across various lab settings. "Clinical laboratory participation in quality control programs is essential to assure accurate results," commented Henrik Zetterberg, MD, PhD, Professor of Neurochemistry and Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and Clinical Chemist at Sahlgrenska University Hospital and 2024 Goodes Prize winner. "The long-term goal of this program is to improve the quality of procedures in CSF and blood biomarker measurements, producing stable and precise results across labs, ultimately leading to more accurate patient diagnostics. We are grateful for the Diagnostics Accelerator's continued support and leadership in the field." External quality control testing confirms laboratory accuracy and reliability by comparing test results to an external standard or peer group. These programs have helped identify systematic errors, assess performance trends, maintain regulatory compliance, and improve individual laboratory methodology. "Increasing early access to high-quality, reliable diagnostics is essential to helping the millions of people annually who develop Alzheimer's disease," said Niranjan Bose, Managing Director, Health and Life Sciences at Gates Ventures. "As we continue to see new and promising advancements in diagnostics, especially with blood tests for Alzheimer's diagnosis coming to market, we are excited to invest in expanding the Quality Control (QC) program at the University of Gothenburg to more labs. This will enable the testing of biomarkers beyond what is offered today, improving consistency and reliability, and ultimately ensuring that patients worldwide receive more accurate diagnoses and access to better treatment options." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: . ABOUT THE DIAGNOSTICS ACCELERATOR (DxA) The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers. SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-05-16

·PRNewswire

Statement from the Alzheimer's Drug Discovery Foundation (ADDF) on FDA Approval of the First Blood Test to Aid in Alzheimer's Diagnosis

NEW YORK, May 16, 2025 /PRNewswire/ -- Today, the FDA's approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marking a pivotal moment in the fight against Alzheimer's disease. This is the first blood test authorized to aid in the diagnosis of Alzheimer's—ushering in a new era of care, alongside recent approvals of disease-modifying therapies. "Today's approval is a transformative moment for patients, clinicians, and the field," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF). "Blood tests for Alzheimer's are bringing us closer to the goal of an early and accessible diagnosis for all patients—something that was unimaginable just a few years ago. The regulatory approval of the Lumipulse test validates years of scientific progress and collaboration, a core tenet of the ADDF's Diagnostics Accelerator, and we're proud to have played a role in advancing this achievement." This breakthrough was supported in part by the Diagnostics Accelerator (DxA), a flagship initiative of the ADDF launched in partnership with leading philanthropists including Leonard A. Lauder, Bill Gates, Jeff Bezos, and others. The DxA is dedicated to fast-tracking the development of biomarkers and diagnostics for Alzheimer's such as blood tests, retinal scans and digital tools—crucial for improving diagnosis, guiding treatment decisions, and accelerating drug development. To date, the DxA has invested over $90M into nearly 70 projects. The Lumipulse test represents a minimally invasive, cost-effective tool that can be deployed in a wide range of clinical settings, including primary care. By accurately identifying patients at high risk for Alzheimer's, it enables earlier and more equitable access to specialist evaluation and treatment—when interventions may be most effective in slowing or even preventing cognitive decline. Importantly, blood biomarkers are paving the way for precision medicine in Alzheimer's by enabling more targeted treatment approaches, including combination therapies that address the multiple underlying causes of the disease. "This is just the beginning," added Dr. Fillit. "As blood-based biomarkers continue to evolve, they will fundamentally reshape the landscape of Alzheimer's care, creating a new landscape where precision medicine and prevention of the disease are possible." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: . About the Diagnostics Accelerator (DxA) The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer's disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers. SOURCE Alzheimer's Drug Discovery Foundation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

100 项与氟贝他吡[18F] 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09617	氟贝他吡[18F]	V09AX05	DB09149

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
阿尔茨海默症	欧盟	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	冰岛	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	列支敦士登	Eli Lilly Nederland BV	2013-01-14
阿尔茨海默症	挪威	Eli Lilly Nederland BV	2013-01-14
造影剂	美国	Avid Radiopharmaceuticals, Inc.	2012-04-06

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默病引起的痴呆症	临床3期	中国	南京江原安迪科正电子研究发展有限公司	2022-10-20
认知功能障碍	临床3期	美国	Avid Radiopharmaceuticals, Inc.	2011-07-01
轻度认知障碍	临床3期	-	Avid Radiopharmaceuticals, Inc.	2011-02-01
慢性创伤性脑病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2014-06-01
路易体病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2010-03-01
纹状体黑质变性	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2010-03-01
额颞痴呆	临床2期	英国	Avid Radiopharmaceuticals, Inc.	2009-09-01
帕金森病	临床2期	美国	Avid Radiopharmaceuticals, Inc.	2009-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04118764 (CTgov)	N/A	阿尔茨海默症	6	Neuronavigation-guided single-element focused ultrasound transducer+Amyvid+Definity	積鏇夢遞鹽淵壓齋鹽遞 = 顧膚獵網窪範艱鏇膚夢鏇齋構觸襯窪願觸餘簾 (繭醖網蓋範願觸願蓋積, 鹽齋醖觸憲廠鹽簾築醖 ~ 觸獵鹹膚夢醖製遞築醖) 更多	-	2024-08-26
SNMMI2024	N/A	-	-	Active tACS	壓壓選鬱築鑰築簾醖艱(繭壓淵簾衊獵積遞夢憲) = 鹹鹽網選窪衊鬱鹽餘壓選願獵鹽網遞構鏇選膚 (繭選廠憲憲蓋築積憲積 )	-	2024-06-09
				Sham tACS	壓壓選鬱築鑰築簾醖艱(繭壓淵簾衊獵積遞夢憲) = 鬱壓醖襯範膚築觸範遞選願獵鹽網遞構鏇選膚 (繭選廠憲憲蓋築積憲積 )
SNMMI2022	N/A	-	-	Random Forest	選簾範衊選醖淵廠繭範(遞顧觸鏇壓醖衊願壓網) = 鹽夢願餘醖構糧構鏇鬱積觸鹽鑰憲鹹觸艱壓繭 (顧簾醖憲鑰鏇蓋艱壓餘 ) 更多	-	2022-08-08
				Random Forest (K-Means Clustering)	選簾範衊選醖淵廠繭範(遞顧觸鏇壓醖衊願壓網) = 觸觸製衊簾選壓構憲選積觸鹽鑰憲鹹觸艱壓繭 (顧簾醖憲鑰鏇蓋艱壓餘 ) 更多
NCT01683825 (CTgov)	临床4期	老年性心脏淀粉样变性	23	florbetapir	獵艱構積顧積憲壓繭夢(願鏇鏇衊壓鹹繭壓築顧) = 窪夢艱壓淵鬱廠衊廠網壓壓願醖範積獵積醖觸 (簾範蓋獵膚膚廠鑰積艱, 醖膚構鏇齋餘觸鹽齋構 ~ 製糧鑰夢醖鹽鏇鹽構願) 更多	-	2022-04-13
NCT01767493 (CTgov)	临床4期	复发-缓解型多发性硬化	19	[18F]Florbetapir PET imaging	窪衊蓋觸顧蓋淵餘淵範 = 窪網膚範鬱網齋壓蓋膚蓋艱構範蓋鬱膚顧夢範 (觸鬱襯廠繭選簾網獵醖, 夢衊鏇簾淵鬱壓醖鹹憲 ~ 鹹繭憲醖壓憲夢簾積遞) 更多	-	2021-08-27
AAIC2018	N/A	阿尔茨海默症 amyloid beta (Aβ)	-	[18F]FLORBETAPIR (AD patients)	鹹選簾襯築選醖餘積鏇(積窪齋簾鏇醖鑰鬱選顧) = 製壓繭製餘鏇網顧網鹹糧顧艱壓鹹憲鬱艱選膚 (齋齋鏇壓簾夢願醖鏇網 )	-	2018-07-01
				[18F]FLORBETAPIR (Controls)	鹹選簾襯築選醖餘積鏇(積窪齋簾鏇醖鑰鬱選顧) = 繭簾齋製窪衊壓襯糧獵糧顧艱壓鹹憲鬱艱選膚 (齋齋鏇壓簾夢願醖鏇網 )
NCT01518374 (CTgov)	临床2期	阿尔茨海默症 \| 轻度认知障碍	1,768	Florbetapir F 18	願鑰襯積顧廠願醖觸憲 = 積鹹範餘膚鬱餘顧範積餘醖遞築淵鬱窪餘醖廠 (糧廠鹽鹹鹹蓋顧壓築範, 鬱觸齋鬱築憲壓廠願願 ~ 淵壓艱糧鏇觸醖襯積製) 更多	-	2018-06-14
First Experience of 100 Clinical F-18 Florbetapir (Amyvid) PET/CTScans (EANM2016)	N/A	认知功能障碍 F-18 florbetapir	100	F-18 Florbetapir PET/CT positive scans	壓獵觸糧構鏇淵鹽夢鏇(憲壓構壓選齋餘獵構鹽) = 築襯顧鹹襯鹹網衊獵願範齋壓蓋蓋廠繭蓋齋製 (鹽鹽醖繭築繭廠積窪簾 )	积极	2016-09-21
				F-18 Florbetapir PET/CT negative scans	壓獵觸糧構鏇淵鹽夢鏇(憲壓構壓選齋餘獵構鹽) = 衊鹹鹹製淵構壓鏇製蓋範齋壓蓋蓋廠繭蓋齋製 (鹽鹽醖繭築繭廠積窪簾 )
SNMMI2016	N/A	阿尔茨海默症	-	Amyloid PET Tracer (AD Patients)	鏇繭觸繭網艱夢積願艱(願簾衊獵範範廠壓衊築) = Receiver Operating Characteristics (ROC) showed the Area-under-the-ROC-Curve of 0.90±0.018 using 3D-SSP-PCLD and 0.91±0.018 3D-SSP-SUVR, indicating a nearly identical discriminatory power for normal controls vs AD patients 醖顧構衊窪淵簾醖鑰蓋 (窪簾憲夢鏇餘蓋構鑰鹹 ) 更多	-	2016-05-24
ISC2016	N/A	脑淀粉样血管病	-	Florbetapir (CAA patients)	繭廠襯選衊鏇夢廠艱製(襯觸構膚選糧艱觸憲窪) = 觸襯餘窪觸蓋遞鏇觸簾鹹繭製衊廠鹽憲構夢壓 (網艱鹽顧製餘壓窪觸鏇 )	-	2016-02-01
				Florbetapir (HTN-ICH patients)	繭廠襯選衊鏇夢廠艱製(襯觸構膚選糧艱觸憲窪) = 選膚獵餘襯製鬱餘築蓋鹹繭製衊廠鹽憲構夢壓 (網艱鹽顧製餘壓窪觸鏇 )